NDAORALTABLET
Approved
Oct 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THIOSULFIL (sulfamethizole) is an oral sulfonamide antibiotic tablet approved in 1953 for bacterial infections. The drug works by inhibiting bacterial folate synthesis, making it bacteriostatic against susceptible gram-positive and gram-negative organisms. It represents a legacy small-molecule antibiotic from the pre-modern era of infectious disease treatment.
LOE Approaching
Product is in late-stage lifecycle with minimal growth opportunities; team size likely lean focused on brand maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on THIOSULFIL offers minimal career growth and visibility; the product is in managed decline with zero linked job openings. Career development would focus on operational efficiency, formulary defense, and cost-management rather than innovation or market expansion.
Brand Manager (Legacy)Medical Science Liaison (Niche)
Worked on THIOSULFIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.